P53 Deficiency Accelerate Esophageal Epithelium Intestinal Metaplasia Malignancy
暂无分享,去创建一个
Yinnan Chen | Xiaolong Guo | Gaixia Liu | J. She | X. Hu | G. Guo | Tianyu Yu | Haowei Zhang | Quanpeng Qiu | X. Hu | Xiake Hu | Yinnan Chen
[1] S. Spechler,et al. Mechanisms and pathophysiology of Barrett oesophagus , 2022, Nature Reviews Gastroenterology & Hepatology.
[2] S. Sihag,et al. The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] Suyong Choi,et al. A p53-Phosphoinositide Signalosome Regulates Nuclear Akt Activation , 2021, bioRxiv.
[4] Xiaoying Hu,et al. The JAK/STAT signaling pathway: from bench to clinic , 2021, Signal Transduction and Targeted Therapy.
[5] S. Killcoyne,et al. Evolution and progression of Barrett’s oesophagus to oesophageal cancer , 2021, Nature Reviews Cancer.
[6] Yuquan Wei,et al. Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment , 2021, Cell proliferation.
[7] A. Thrift. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer , 2021, Nature Reviews Gastroenterology & Hepatology.
[8] J. Lagergren,et al. Gastroesophageal Reflux Disease. , 2020, JAMA.
[9] A. Bass,et al. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett’s Esophagus Regardless of a Diagnosis of Dysplasia , 2020, medRxiv.
[10] S. Killcoyne,et al. Genomic copy number predicts esophageal cancer years before transformation , 2020, Nature Medicine.
[11] D. Tweardy,et al. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution , 2020, Pharmacological Reviews.
[12] P. V. van Dam,et al. The potential and controversy of targeting STAT family members in cancer. , 2020, Seminars in cancer biology.
[13] V. Jobanputra,et al. High‐resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma , 2019, International journal of cancer.
[14] Yonne Peters,et al. Barrett oesophagus , 2019, Nature Reviews Disease Primers.
[15] Alireza Hadj Khodabakhshi,et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.
[16] M. Bulyk,et al. The multiple mechanisms that regulate p53 activity and cell fate , 2019, Nature Reviews Molecular Cell Biology.
[17] Wei Zhang,et al. Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's Cells. , 2019, Gastroenterology.
[18] Nicholas D. Camarda,et al. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. , 2018, Gastroenterology.
[19] Jing Yan,et al. Targeting VEGF/VEGFR to Modulate Antitumor Immunity , 2018, Front. Immunol..
[20] A. Thrift. Barrett’s Esophagus and Esophageal Adenocarcinoma: How Common Are They Really? , 2018, Digestive diseases and sciences.
[21] C. Caldas,et al. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. , 2017, Gastroenterology.
[22] J. Lagergren,et al. The Epidemiology of Esophageal Adenocarcinoma. , 2017, Gastroenterology.
[23] S. Imbeaud,et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.
[24] Scott W. Lowe,et al. Putting p53 in Context , 2017, Cell.
[25] Geet Duggal,et al. Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference , 2017, Nature Methods.
[26] P. Taylor,et al. Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort , 2017, Gut.
[27] P. Thota,et al. Expression of p53 predicts risk of prevalent and incident advanced neoplasia in patients with Barrett's esophagus and epithelial changes indefinite for dysplasia , 2015, Gastroenterology report.
[28] J. Wilson,et al. Gastroesophageal Reflux Disease , 2008, North Carolina Medical Journal.
[29] A. Gavin,et al. Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5. , 2015, European journal of cancer.
[30] P. Fockens,et al. Aberrant TP53 detected by combining immunohistochemistry and DNA‐FISH improves Barrett's esophagus progression prediction: A prospective follow‐up study , 2015, Genes, chromosomes & cancer.
[31] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[32] E. Kuipers,et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus , 2012, Gut.
[33] W. El-Rifai,et al. Glutathione peroxidase 7 protects against oxidative DNA damage in oesophageal cells , 2011, Gut.
[34] H. Sørensen,et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. , 2011, The New England journal of medicine.
[35] N. Carter,et al. Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.
[36] S. Spechler,et al. Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. , 2010, Gastroenterology.
[37] R. Sutton,et al. TP53 mutations in malignant and premalignant Barrett's esophagus. , 2003, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[38] S. Spechler. Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. , 2002, Gastroenterology.
[39] D. Hicklin,et al. Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.
[40] H Feussner,et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. , 1997, Surgery.
[41] D. Gotley,et al. Composition of gastro-oesophageal refluxate. , 1991, Gut.